Cellectar Biosciences, Inc.

Our Clinical Trials

Clinical Trials for CLR 131

CLR 131 is a small-molecule, cancer-targeting radiotherapeutic PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. CLR 131 is our lead therapeutic PDC product candidate and is currently being evaluated in both Phase 1 and Phase 2 clinical studies.

Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)

This study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma(

Status

Recruiting

Relapsed or Refractory Select B-Cell Malignancies Clinical Trial: View Clinical Trial

Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

The study evaluates CLR 131 in children and adolescents with relapsed or refractory malignant

Status

Recruiting

Children With Relapsed or Refractory Malignant Cancer Clinical Trial: View Clinical Trial

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

The primary objective of the study is to determine the safety and tolerability of

Status

Active, not recruiting

Relapsed or Refractory Multiple Myeloma Clinical Trial: View Clinical Trial

Enrollment

For more information on enrollment into our current clinical trials, please contact us or visit clinicaltrials.gov for location information.

Contact Us Visit ClinicalTrials.gov

Expanded Access Policy

Learn More